Pollen specific immunotherapy is not a risk factor for de novo sensitization to cross-reacting allergens in monosensitized subjects.
Some studies have suggested that specific immunotherapy (SIT) may cause de novo sensitization to allergenic proteins to which patients were not previously allergic. This event might theoretically involve cross-reacting pollen allergens, such as profilin or polcalcins, posing a risk of SIT-induced polysensitization to pollens in patients who were originally monosensitized. The aim of this study was to assess whether injection SIT with commercial pollen extract represents a risk factor for the de novo development of sensitization to different pollens in monosensitized patients. The study involved 142 subjects diagnosed as being monosensitized to a single pollen: 64 patients who were administered a 3-year course of injection SIT and 78 controls. Subjects underwent control skin prick tests (SPT) with a series of 8 seasonal airborne allergens at least 3 years after the first visit. Patients with 5 or more new sensitivities on SPT were considered to be de novo polysensitized. At the end of the 3-year follow-up period, the proportion of polysensitized subjects was identical in previously monosensitized patients who underwent SIT and control individuals (11% and 10%, respectively). Individuals who were polysensitized were significantly younger than those who were not (mean age +/- SD, 21.6 +/- 11.0 years vs. 31.6 +/- 15.6 years; P < .05). SIT does not represent a risk factor for progression towards multiple pollen sensitization in monosensitized pollen-allergic patients.